Biontech Se Sponsored Adr Stock News

Pfizer reported its net income in 2021 at nearly $22 billion, more than double the figure for 2020. Revenue surged 95% to $81.3 billion, boosted by the covid vaccine it developed with Germany’s BioNTech. It now expects its new oral covid pill, Paxlovid, to deliver big bucks in 2022. Its shareholders are pleased

The European Medicines Agency (EMA) has announced that it has started evaluating an application for the use of a booster dose of Comirnaty (BioNTech/Pfizer’s vaccine) in adolescents aged 12 to 15 years. An application for the booster in older adolescents aged 16 to 17 years is also ongoing. A booster dose of Comirnaty can currently be […]

Heidelberg, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company''s Heidelberg facility. According to a recent news release from Pfizer and BioNTech , the companies have started to develop an Omicron-based COVID-19 vaccine with first batches expected to be ready for delivery by end of March 2022. "We are proud to continue to support BioNTech and supply them with pDNA materials for their vaccine production, as a part of the fight against new pandemic variants," said AGC Biologics Chief Executive Officer, Patricio Massera. "Our pDNA services … Full story available on Benzinga.com

BioNTech had a rough Tuesday with shares closing down 7.6%.

The pandemic has been transformational for many businesses, but few can boast near-global domination the way Pfizer (PFE) can. The Pfizer/BioNTech (BNTX) vaccine accounts for 70% of all doses in the U.S. and E.U., as of February 5, according to CEO Albert Bourla Tuesday.

WASHINGTON: Pfizer said yesterday it expects $32 billion in revenue from COVID-19 vaccines in 2022 as it reported annual profits had more than doubled to $22 billion. The pharmaceutical giant, which with German company BioNTech won approval for the first vaccine to counter the deadly virus, saw annual revenues nearly double to $81.3 billion, with $36.8 billion from the COVID-19 vaccine. Pfizer also expects $22 billion in sales of Paxlovid, the companys pill for COVID-19, in 2022. The results are the latest to show how the coronavirus has transformed Pfizer, which a year ago had projected just $15 billion in COVID-19 vaccines sales in 2021 and ended up selling more than twice that amount after repeatedly lifting the forecast. Pfizers scientists continue to monitor the COVID-19 virus and believe it is unlikely that it will be fully eradicated in the foreseeable future, Chief Executive Albert Bourla said in a statement. That said, we now have the tools-in the forms of vaccines and treatments-that we believe will help enable us to not only better manage the pandemic but also help countries move into the endemic phase, Bourla said. In other words, we believe these tools will help allow us to go back to normality and spend time with family and friends, travel, attend indoor dining and concerts, and enjoy many other activities while lowering the risk of overburdening hospitals and healthcare systems around the world. Although Pfizers profit per share topped analyst expectations, revenues fell short.

Although Pfizer raised its forecast for the vaccine, developed with Germany''s BioNTech SE, by $1 billion to $32 billion, the drugmaker cautioned that final sales for the year may not top that figure. Last year, the company increased its COVID vaccine sales forecast several times as it signed more deals to supply it around the world.

Pfizer projected Tuesday that it will generate a record-shattering $32 billion in revenue from its publicly funded coronavirus vaccine in 2022 as the U.S. pharmaceutical giant refuses to share its technology with other nations, leaving billions of people around the world without access to lifesaving shots as the pandemic continues to rage. "Big Pharma has made more than enough money from this crisis," said the U.K.-based advocacy group Global Justice Now. "It''s time to suspend patents and break vaccine monopolies." While a portion of Pfizer''s mRNA-based vaccine recipe was leaked last year, the pharmaceutical firm and its German partner BioNTech have closely guarded the details of their manufacturing process, allowing the companies to rake in huge profits by selling their Covid-19 shots at a price tag well above the cost of production. On Tuesday, Pfizer reported that its profits increased roughly fourfold to $3.4 billion in the fourth quarter of 2021, beating analysts'' expectations. "It''s nothing short of pandemic profiteering for Pfizer to make a killing while its vaccines have been withheld from so many," Tim Bierley, a pharma campaigner at Global Justice Now, said in a statement. "Pfizer is now richer than most countries; it has made more than enough money from this crisis." In an analysis published in July, The People''s Vaccine Alliance noted that "Pfizer/BioNTech are charging their lowest reported price of $6.75 [per dose] to the African Union, but this is still nearly six times more than the estimated potential production cost of this vaccine." "One dose of the vaccine costs the same as Uganda spends per citizen on health in a whole year," the coalition observed.

NEW YORK: Pfizer said Tuesday (Feb 8) it expects US$32 billion in revenue from COVID-19 vaccines in 2022 as it reported annual profits had more than doubled to US$22 billion. The pharmaceutical giant, which with German company BioNTech won approval for the first vaccine to counter the deadly virus, saw ann

Shares of Pfizer Inc. sank 2.6% in premarket trading Tuesday, after the drug maker reported fourth-quarter profit that beat expectations, while revenue more than doubled but missed forecasts. The company also provided a full-year outlook that was below analyst projections, but raised its sales guidance for its COVID-19 vaccine Comirnaty developed with BioNTech SE . Net income jumped to $3.39 billion, or 59 cents a share, from $847 million, or 15 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share rose to $1.08 from 43 cents, above the FactSet consensus of 87 cents. Revenue grew 104.9% to $23.84 billion, but missed the FactSet consensus of $24.16 billion, with Comirnaty contributing $12.5 billion in sales to beat expectations of $12.38 billion. For 2022, the company raised its sales outlook for Comirnaty to $32 billion from $31 billion, and expects $22 billion of revenue for its oral COVID-19 treatment Paxlovid. Overall, the company expect adjusted EPS of $6.35 to $6.55, below the current FactSet consensus of $6.71, and expects revenue of $98.0 billion to $102.0 billion, below expectations of $103.2 billion.

The South African Health Products Regulatory Authority ((SAHPRA)) registered Pfizer (PFE) and BioNTech''s (BNTX) vaccine COMIRNATY and the COVID-19 vaccine MC PHARMA, also known as

Callable Multi Barrier Reverse Convertible auf BioNTech, Johnson & Johnson, Merck, Moderna, Pfizer / Idorsia, Lonza, Novartis, Roche, Zur Rose Group AG

At the urging of the federal government, Pfizer and its partner BioNTech applied last week for authorization for two doses of its Covid vaccine to children aged 4 and younger.

Technical analysis for Biontech Se BNTX including support levels resistance levels and stop losses for BNTX

Germany''s expert panel on vaccine use has recommended Novavax Inc''s (NASDAQ: NVAX ) protein-based COVID-19 vaccine for primary immunization for people over 18 years. The advisory group known as STIKO said a booster shot should still be given with an mRNA vaccine, reported Reuters. mRNA technology is behind the two most commonly used COVID-19 vaccines from - Pfizer Inc (NYSE: PFE ) / BioNTech SE (NASDAQ: BNTX ) and Moderna Inc (NASDAQ: MRNA ). Novavax''s COVID-19 vaccine NVX-CoV2373 is Full story available on Benzinga.com